Professor of Vascular Surgery, Ain Shams University, Cairo, Egypt.
Thromb J. 2012 Sep 5;10(1):20. doi: 10.1186/1477-9560-10-20.
Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However, the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE study in Egypt is part of a global initiative to uncover the incidence of high-risk surgical and medical patients and determine what proportion of these patients receive appropriate VTE prophylaxis.
Ten Egyptian hospitals participated in this observational study, enrolling all surgical and medical patients that met the study criteria. This resulted in a cohort of 1,008 patients in acute care facilities who underwent a retrospective chart review. Each patient's VTE risk status and the presence or absence of appropriate prophylactic care was assessed according to the American College of Chest Physicians (ACCP) guidelines 2004.
Of the 1,008 patients enrolled, 395 (39.2%) were found to be at high-risk for VTE. Overall, 227 surgical patients were at high-risk, although only 80 (35.2%) received ACCP-recommended prophylaxis. Similarly, 55/268 (32.75%) of high-risk medical patients received appropriate VTE prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant, while mechanical prophylactic use was quite low (1.5%) in high-risk patients.
In Egypt, more than one-third of all patients hospitalized for surgery or acute medical conditions are at high risk for developing VTE. However, only a small fraction of these patients receive appropriate VTE prophylaxis. Corrective measures are necessary for preventing VTE morbidity and mortality in these high risk patients.
静脉血栓栓塞症(VTE)是全球范围内导致医院相关死亡的主要原因。然而,在埃及,有多少处于 VTE 风险中的患者接受了适当的预防措施尚不清楚。埃及的 ENDORSE 研究是一项全球性计划的一部分,旨在发现高危外科和内科患者的发病率,并确定这些患者中有多少人接受了适当的 VTE 预防措施。
10 家埃及医院参与了这项观察性研究,共纳入符合研究标准的所有外科和内科患者。这导致了 1008 名在急性护理设施中接受回顾性病历审查的患者队列。根据美国胸科医师学会(ACCP)2004 年指南,评估每位患者的 VTE 风险状况和是否存在适当的预防护理。
在纳入的 1008 名患者中,发现有 395 名(39.2%)患者有发生 VTE 的高度风险。总体而言,有 227 名外科患者处于高度风险,但仅有 80 名(35.2%)接受了 ACCP 推荐的预防措施。同样,有 55/268(32.75%)名处于高度风险的内科患者接受了适当的 VTE 预防措施。低分子肝素是最常用的抗凝剂,而在高危患者中,机械预防的使用率相当低(1.5%)。
在埃及,超过三分之一因手术或急性内科情况住院的患者有发生 VTE 的高度风险。然而,这些患者中只有一小部分接受了适当的 VTE 预防措施。需要采取纠正措施,以预防这些高危患者中的 VTE 发病率和死亡率。